LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data

Gong, Yiwen; Sui, Zichao; Lv, Yinghua; Zheng, Qingshan; Li, Lujin

doi:10.1007/s00228-023-03543-y

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A random-effects model in a single-arm meta-analysis was used to summarize the model parameters for different targeted drugs. Finally, Monte Carlo simulations (1,0000 times) were used to obtain the typical OS and PFS time curves and their 95% CIs for two types of targeted drugs [14].…”

Section: Model Predictionmentioning

confidence: 99%

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer

Pan,

Lin,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2- metastatic breast cancer. Methods A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3–4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. Results This study included 44 arms from 48 publications, with a total sample size of 7,881 patients. Our study revealed that CDK4/6 inhibitors had a median OS of 40.7 months, a median PFS of 14.8 months, and ORR of 40%. Whereas, PI3K/AKT/mTOR inhibitors had a median OS of 29.8 months, a median PFS of 8.3 months, and ORR of 20%. Additionally, this study also found that the proportion of patients with visceral metastases and specific endocrine therapy used in combination significantly impact OS and PFS. In terms of adverse events, CDK4/6 inhibitors exhibited a relatively high incidence of hematological adverse events. Conclusion Our study provides solid quantitative evidence for the first-line recommendation of CDK4/6 inhibitors combined with endocrine therapy for ER+/HER2- metastatic breast cancer in clinical guidelines.

show abstract

Section: Model Predictionmentioning

confidence: 99%

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer

Pan,

Lin,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer

Pan,

Lin,

Liu

et al. 2024

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The aim of this study was to quantitatively compare the e cacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2-metastatic breast cancer. MethodsA parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3-4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. ResultsThis study included 44 arms from 48 publications, with a total sample size of 7,881 patients. Our study revealed that CDK4/6 inhibitors had a median OS of 40.7 months, a median PFS of 14.8 months, and ORR of 40%. Whereas, PI3K/AKT/mTOR inhibitors had a median OS of 29.8 months, a median PFS of 8.3 months, and ORR of 20%. Additionally, this study also found that the proportion of patients with visceral metastases and speci c endocrine therapy used in combination signi cantly impact OS and PFS. In terms of adverse events, CDK4/6 inhibitors exhibited a relatively high incidence of hematological adverse events. ConclusionOur study provides solid quantitative evidence for the rst-line recommendation of CDK4/6 inhibitors combined with endocrine therapy for ER+/HER2-metastatic breast cancer in clinical guidelines.

show abstract

LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data

Cited by 2 publications

References 37 publications

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2- metastatic breast cancer

Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer

Contact Info

Product

Resources

About